Genmab A/S Expands US Presence with New Jersey Site to Drive Global Growth

Genmab A/S, a Danish biotech company, has opened a major new US site in New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. The company's oncology portfolio continues to gain traction, with full FDA approval for Tivdak and strong sales growth for Epkinly. Genmab's pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. The company continues to benefit from its collaboration with Johnson & Johnson on DARZALEX and is focused on long-term growth through talent retention and investment.